MX2017007232A - Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes. - Google Patents

Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.

Info

Publication number
MX2017007232A
MX2017007232A MX2017007232A MX2017007232A MX2017007232A MX 2017007232 A MX2017007232 A MX 2017007232A MX 2017007232 A MX2017007232 A MX 2017007232A MX 2017007232 A MX2017007232 A MX 2017007232A MX 2017007232 A MX2017007232 A MX 2017007232A
Authority
MX
Mexico
Prior art keywords
biologics
antigens
proteins
mobility shift
present
Prior art date
Application number
MX2017007232A
Other languages
English (en)
Inventor
Singh Sharat
Chi-Kwan Ling Nicholas
Westin Stefan
Jain Anjali
SALBATO Jared
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2017007232A publication Critical patent/MX2017007232A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona un ensayo de desplazamiento por movilidad homogéneo indirecto sensible y específico que usa cromatografía de exclusión de tamaño para medir productos biológicos tales como vedolizumab y ustekinumab en una muestra de paciente. Los ensayos de la presente invención son particularmente adecuados para detectar la presencia o el nivel de productos biológicos que se dirigen a antígenos complejos o grandes incluyendo proteínas de superficie celular, proteínas de transmembrana, proteínas fuertemente glicosiladas y proteínas multiméricas, así como antígenos que no pueden ser purificados, antígenos impuros, y antígenos parcialmente o sustancialmente purificados. La presente invención también proporciona heterodímeros de integrina a4ß7 solubles y aislados, y monómeros de IL-12p40 solubles y aislados que son adecuados para su uso en los ensayos indirectos descritos en la presente.
MX2017007232A 2014-12-05 2015-12-04 Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes. MX2017007232A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462088465P 2014-12-05 2014-12-05
US201562113317P 2015-02-06 2015-02-06
US201562158791P 2015-05-08 2015-05-08
PCT/IB2015/059381 WO2016088104A2 (en) 2014-12-05 2015-12-04 Indirect homogeneous mobility shift assays for the detection of biologics in patient samples

Publications (1)

Publication Number Publication Date
MX2017007232A true MX2017007232A (es) 2017-10-16

Family

ID=55025290

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007232A MX2017007232A (es) 2014-12-05 2015-12-04 Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.

Country Status (15)

Country Link
US (3) US10422807B2 (es)
EP (2) EP3536705A1 (es)
JP (1) JP2018500553A (es)
KR (1) KR20170091717A (es)
CN (1) CN107250798A (es)
AU (1) AU2015356613A1 (es)
BR (1) BR112017011545A2 (es)
CA (1) CA2969609C (es)
ES (1) ES2735085T3 (es)
HK (1) HK1244880B (es)
IL (1) IL252396A0 (es)
MX (1) MX2017007232A (es)
RU (1) RU2017122720A (es)
SG (1) SG11201704200SA (es)
WO (1) WO2016088104A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2494352B1 (en) 2009-10-26 2020-04-08 Prometheus Biosciences, Inc. Assays for the detection of anti-tnf drugs and autoantibodies
JP6181646B2 (ja) 2011-07-06 2017-08-16 ネステク ソシエテ アノニム Ｔｎｆアルファによる生物学的治療に対する中和自己抗体の検出のためのアッセイ
KR20170091717A (ko) * 2014-12-05 2017-08-09 네스텍 소시에테아노님 환자 샘플 중 생물제제의 검출을 위한 간접적 균질 이동성 변화 검정
CN114624343B (zh) * 2020-12-10 2023-01-24 中国科学院大连化学物理研究所 一种用于血清中45种炎症及免疫代谢物相对定量的方法
AU2022359021A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
CA3234496A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3107755A1 (de) 1981-02-28 1982-09-16 Degussa Ag, 6000 Frankfurt Katalysatoren fuer die herstellung von 3-cyanpyridin
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4459359A (en) 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4857456A (en) 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
US5094740A (en) 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
JPH04303867A (ja) 1991-03-30 1992-10-27 Toshiba Corp 画像形成装置
US5582998A (en) 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
JPH0566222A (ja) 1991-09-09 1993-03-19 Tosoh Corp 物質の分析方法
PT672141E (pt) * 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DE69426223T2 (de) 1993-09-07 2001-05-23 Wako Pure Chem Ind Ltd Verfahren und Reagenz zur Messung der Komplementaktivität
JPH07110331A (ja) 1993-09-07 1995-04-25 Wako Pure Chem Ind Ltd ヒト補体価測定方法及びヒト補体価測定用試薬組成物
JPH07140144A (ja) 1993-11-19 1995-06-02 S R L:Kk アレルゲン特異的ＩｇＥ抗体の測定方法および抗原抗体複合体の測定方法
CA2209360C (en) 1994-12-28 2010-07-06 University Of Kentucky Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
US6903183B1 (en) 1996-06-07 2005-06-07 Texas Tech University Health Services Center Compositions and methods for regulation of steroidogenesis
JP3718435B2 (ja) 1996-08-12 2005-11-24 積水化学工業株式会社 細胞機能測定用容器及び細胞機能測定方法
AU727500B2 (en) 1996-08-12 2000-12-14 Sekisui Kagaku Kogyo Kabushiki Kaisha Container for measurement of cell functions, kit for measurement of cell functions and method for measuring cell functions
US6391622B1 (en) 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
DE19858777B4 (de) 1998-12-18 2006-07-27 Delta Biotechnology Ltd. Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
AU2262501A (en) 1999-12-16 2001-06-25 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
WO2002081518A2 (en) * 2001-02-21 2002-10-17 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
EP1637601A3 (en) * 2001-02-21 2006-03-29 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
ATE476654T1 (de) 2001-03-02 2010-08-15 Activx Biosciences Inc Plattform für protein-profiling
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1423135A4 (en) * 2001-08-06 2006-06-07 Univ California PROCESS FOR INHIBITING THE ANGIOGENESIS
WO2003016909A1 (en) 2001-08-16 2003-02-27 Ludwig Institute For Cancer Research Method for determining protein component in a biological sample
MXPA04004417A (es) 2001-11-12 2004-08-11 Merck Patent Gmbh Anticuerpo anti-tnf alfa modificado.
EP1470160A2 (en) 2001-12-05 2004-10-27 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
WO2004012673A2 (en) 2002-08-01 2004-02-12 Wyeth, Methods and reagents relating to inflammation and apoptosis
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7648825B2 (en) 2003-06-20 2010-01-19 University Of Florida Research Foundation, Inc. Biomarkers for differentiating between type 1 and type 2 diabetes
BRPI0413197A (pt) 2003-08-01 2006-10-03 Amgen Inc cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
EP1660538A1 (en) 2003-08-14 2006-05-31 Wyeth Anti-lewis y anti-idiotypic antibodies and uses thereof
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
WO2005072340A2 (en) * 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
WO2006004958A2 (en) 2004-06-30 2006-01-12 Centocor, Inc. Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
KR20080046135A (ko) 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
JP2009501913A (ja) 2005-07-21 2009-01-22 ゲンマブ エー／エス Ｆｃ受容体と結合する抗体原薬に関する効力アッセイ
WO2007037910A2 (en) 2005-09-14 2007-04-05 Fred Hutchinson Cancer Research Center Specific removal of activated immune cells
US7542502B2 (en) 2005-09-27 2009-06-02 Cymer, Inc. Thermal-expansion tolerant, preionizer electrode for a gas discharge laser
WO2007056540A2 (en) 2005-11-08 2007-05-18 Medarex, Inc. Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
JP2007147367A (ja) 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
DE102005057920A1 (de) 2005-12-02 2007-06-28 Strohner, Pavel, Dr. Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben
US20100130367A1 (en) 2006-07-11 2010-05-27 Drexel University Methods of Quantitatively Assessing Inflammation with Biosensing Nanoparticles
EP2064345B1 (en) * 2006-09-11 2013-03-13 Celera Corporation Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
US20080286774A1 (en) * 2007-05-16 2008-11-20 The Regents Of The University Of California Real-time individualized therapy evaluation
AU2008276251B2 (en) 2007-07-13 2014-04-24 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
WO2009091240A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
WO2009126380A2 (en) 2008-03-05 2009-10-15 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
US8877893B2 (en) * 2008-12-29 2014-11-04 Children's Medical Center Corporation Stabilized low affinity conformation of integrins for drug discovery
EP2494352B1 (en) 2009-10-26 2020-04-08 Prometheus Biosciences, Inc. Assays for the detection of anti-tnf drugs and autoantibodies
DK2547359T3 (en) * 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
JP5066222B2 (ja) 2010-05-31 2012-11-07 三菱電機株式会社 ネットワーク解析支援装置、ネットワーク解析支援方法及びプログラム
CN103261222B (zh) * 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
EP2676137B1 (en) 2011-02-17 2014-12-31 Nestec S.A. Assays for detecting autoantibodies to anti-tnf drugs
PE20141672A1 (es) 2011-05-02 2014-11-26 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-alfa4�7
CN103649336A (zh) 2011-05-10 2014-03-19 雀巢产品技术援助有限公司 用于个体化治疗管理的疾病活动性表征方法
CN103796667A (zh) * 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
AU2012277185A1 (en) * 2011-06-30 2014-02-13 Gene Techno Science Co., Ltd. Soluble integrin alpha4 mutant
JP6181646B2 (ja) 2011-07-06 2017-08-16 ネステク ソシエテ アノニム Ｔｎｆアルファによる生物学的治療に対する中和自己抗体の検出のためのアッセイ
US20130266963A1 (en) 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
US20150010563A1 (en) * 2012-02-21 2015-01-08 Massachusetts Eye & Ear Infirmary Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
US20130295685A1 (en) 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
BR112015012482A2 (pt) 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
SG11201602671WA (en) 2013-11-13 2016-05-30 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
KR20170091717A (ko) 2014-12-05 2017-08-09 네스텍 소시에테아노님 환자 샘플 중 생물제제의 검출을 위한 간접적 균질 이동성 변화 검정
KR102423893B1 (ko) 2015-03-31 2022-07-21 삼성디스플레이 주식회사 플렉서블 표시 장치
MX2019006864A (es) 2016-12-14 2019-10-15 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf).

Also Published As

Publication number Publication date
US20240183867A1 (en) 2024-06-06
RU2017122720A (ru) 2019-01-10
JP2018500553A (ja) 2018-01-11
US20170328923A1 (en) 2017-11-16
US10422807B2 (en) 2019-09-24
WO2016088104A2 (en) 2016-06-09
IL252396A0 (en) 2017-07-31
AU2015356613A1 (en) 2017-06-15
ES2735085T3 (es) 2019-12-16
HK1244880B (zh) 2020-06-05
WO2016088104A3 (en) 2016-08-18
US11846642B2 (en) 2023-12-19
SG11201704200SA (en) 2017-06-29
CA2969609C (en) 2023-02-28
CN107250798A (zh) 2017-10-13
EP3227683B1 (en) 2019-04-24
BR112017011545A2 (pt) 2018-03-13
EP3227683A2 (en) 2017-10-11
CA2969609A1 (en) 2016-06-09
KR20170091717A (ko) 2017-08-09
US20200088749A1 (en) 2020-03-19
EP3536705A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
MX2017007232A (es) Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
AU2018200278B2 (en) Antibodies to aripiprazole and use thereof
MX2017015011A (es) Ensayo a base de celulas para detectar homodimeros anti-cd3.
SG10201908167YA (en) Proximity assays for detecting nucleic acids and proteins in a single cell
MX366275B (es) Metodos para detectar y medir la agregacion.
CO2017002710A2 (es) Sistemas y métodos para la integración de la recolección de microfluido lagrimal y el análisis por flujo lateral de analitos de interés
MX2020001227A (es) Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
MX2017003269A (es) Detección de las proteínas mal plegadas.
WO2011119934A3 (en) Methods and materials for detecting colorectal neoplasm
EP3933406A3 (en) Antibodies to risperidone and use thereof
IN2015DN01876A (es)
MX2016001573A (es) Ensayos para timp2 con mejor rendimiento en muestras biológicas.
CL2019002264A1 (es) Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet.
WO2013165972A3 (en) Anti-hepatitis b virus antibodies and use thereof
WO2016209773A9 (en) Improved assays and methods for allergen detection
MX2015001961A (es) Metodos y sistemas para ensayos.
IT201600073964A1 (it) Nanointerruttore basato su nucleotidi e metodi per la rilevazione di anticorpi e altri analiti
WO2015023503A3 (en) Compositions and methods for multimodal analysis of cmet nucleic acids
MX2015004419A (es) Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables.
SG10201806729VA (en) Novel assay to detect human periostin
MX2016010499A (es) Sistemas y métodos para identificar subtipos del receptor de progesterona.
WO2015134928A3 (en) Point of care assays to detect the status of tuberculosis infection
WO2014151290A3 (en) Assay for predictive biomarkers
BR112018013381A2 (pt) anticorpo especificamente ligante a antígenos derivados de miobacteria ou fragmento ligante a antígeno do mesmo